Koers Ampliphi Biosciences Corp Nyse
Aandelen
APHB
US03211P2020
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 4,54 mln. 4,25 mln. | Omzet 2025 * | 2,75 mln. 2,57 mln. | Marktkapitalisatie | 101 mln. 94,06 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -72 mln. -67,38 mln. | Nettowinst (verlies) 2025 * | -67 mln. -62,7 mln. | EV/omzet 2024 * | 22,1 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 36,5 x |
K/w-verhouding 2024 * |
-1,46
x | K/w-verhouding 2025 * |
-2,14
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 29,72% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Deborah Birx
CEO | Chief Executive Officer | 68 | 11-07-23 |
Richard Rychlik
DFI | Director of Finance/CFO | 68 | 05-09-23 |
Mina Pastagia
CTO | Chief Tech/Sci/R&D Officer | - | 26-10-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 64 | 12-02-20 | |
Joseph Patti
BRD | Director/Board Member | 60 | 09-05-19 |
Jules Haimovitz
BRD | Director/Board Member | 73 | 01-04-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+30,56% | 52,73 mld. | |
+37,83% | 39 mld. | |
-9,38% | 38,52 mld. | |
+25,89% | 30,38 mld. | |
-11,17% | 26,39 mld. | |
+10,54% | 26,08 mld. | |
+44,92% | 14,15 mld. | |
+32,95% | 12,6 mld. | |
-5,47% | 11,51 mld. |